BIO-TECHNE Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 1.09 million shares for the 12-month period ending 2018-06-30, per its 10-K filed 2018-08-27.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2018-08-27
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2012-09-30 was 5.00K shares, a 80.00% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2012-06-30 was 0.00 shares.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2012-03-31 was 30.00K shares.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2011-12-31 was 40.00K shares.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2018 was 1.09M shares, a 4.23% decline from fiscal 2017.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2017 was 1.14M shares, a 40.99% increase from fiscal 2016.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2016 was 805.00K shares, a 34.17% increase from fiscal 2015.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 600.00K shares, a 238943.82% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month as first filed |
|---|---|---|---|---|---|
| 2018-06-30 | 1.09M shares 10-K · filed 2018-08-27 | ||||
| 2017-06-30 | 1.14M shares 10-K · filed 2018-08-27 | ||||
| 2016-06-30 | 805.00K shares 10-K · filed 2018-08-27 | 805.00 shares 10-K · filed 2016-08-29 | |||
| 2015-06-30 | 600.00K shares 10-K · filed 2017-09-07 | ||||
| 2014-06-30 | 251.00 shares 10-K · filed 2016-08-29 | 251.00K shares 10-K · filed 2014-08-29 | |||
| 2013-06-30 | 175.00K shares 10-K · filed 2015-08-31 | ||||
| 2012-09-30 | 5.00K shares 10-Q · filed 2012-11-09 | 5.00K shares derived: sum of 2 quarters · filed 2014-08-29 | 35.00K shares derived: sum of 3 quarters · filed 2014-08-29 | 75.00K shares derived: sum of 4 quarters · filed 2014-08-29 | |
| 2012-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | 30.00K shares derived: sum of 2 quarters · filed 2014-08-29 | 70.00K shares derived: sum of 3 quarters · filed 2014-08-29 | 95.00K shares 10-K · filed 2014-08-29 | |
| 2012-03-31 | 30.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-10 | 70.00K shares derived: sum of 2 quarters · filed 2012-05-10 | 95.00K shares 10-Q · filed 2012-05-10 | ||
| 2011-12-31 | 40.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-07 | 65.00K shares 10-Q · filed 2012-02-07 | |||
| 2011-09-30 | 25.00K shares 10-Q · filed 2011-11-09 | ||||
| 2011-06-30 | 188.00K shares 10-K · filed 2013-08-29 | ||||
| 2010-06-30 | 115.00K shares 10-K · filed 2012-08-29 | ||||
| 2009-06-30 | 47.00K shares 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |